China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

Agilent Technologies reported after the close of the market recently that its fiscal first quarter revenues rose 6 percent year over year.

Invitae reported after the close of the market recently that its fourth quarter 2019 revenues increased 47 percent from the prior year.

Diagnostics manufacturer Quidel reported after the close of the market recently that its fourth quarter revenues rose 15 percent year over year, due primarily to growth in its rapid immunoassay business.

Foundation Medicine and Chugai Pharmaceutical said recently they have entered into an agreement with the National Cancer Center Japan to use Foundation's liquid biopsy test as part of an initiative targeting advanced cancer patients.

Bio-Rad Laboratories said after the close of the market recently that its fourth quarter revenues rose approximately 1 percent year over year.

Grail is making some headway in its mission to develop a liquid biopsy solution to detect cancer early. The Menlo Park, CA-based company said it has initiated PATHFINDER, a multi-center study.

Quest Diagnostics said it has acquired Blueprint Genetics in an all-cash equity transaction. Helsinki, Finland-based Blueprint Genetics has deep expertise in gene variant interpretation based on next-generation sequencing (NGS) and proprieta

Researchers at the Laboratory of Bionanophotonic Systems (BIOS) at EPFL's School of Engineering have developed an optical biosensor that slashes the sepsis diagnosis time from several days to just a few minutes. Their approach draws on recen

FDA has issued an emergency use authorization (EUA) for the Centers for Disease Control and Prevention’s Coronavirus detection test. Up until now, the Prevention’s 2019-nCoV Real-Time RT-PCR Diagnostic Panel has only been used at CDC lab

Cardinal Health nixed its relationship with Suqian, China-based Siyang Holymed after learning that the FDA-authorized supplier had shifted production of Cardinal's surgical gowns to non-approved sites without the proper controlled environmen